The next frontier in managing obesity and T2D: The role of novel combinations for touchENDOCRINOLOGY

touchPODCAST

touchEXPERT OPINIONS for touchENDOCRINOLOGY

Listen to three experts discuss the rationale behind glucagon-like peptide-1 (GLP-1)-based combination therapies and review the latest clinical evidence for these novel combinations. The expert faculty will provide their insights on what these combination treatments may mean for the future management of obesity with or without type 2 diabetes (T2D).

The experts

  • Dr Sue Pedersen, University of Calgary, Calgary, Canada
  • Prof. Carel le Roux, University College Dublin, Dublin, Ireland
  • Dr Donna Ryan, Pennington Biomedical Research Center, Baton Rouge, LA, USA

This touchPODCAST is for healthcare professionals outside of the USA and UK.

This activity is funded by an independent medical education grant from Novo Nordisk A/S.

This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider. 

For further information visit our website: 

www.touchENDOCRINOLOGY.com

Content Restricted

This episode cannot be played on the web in your country or region.

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes and get the latest updates.

Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada